"Promising Alzheimer's Drug Donanemab Nears FDA Approval, Offers Hope Amidst Side Effects"

Eli Lilly announced that its drug donanemab, which slows the progression of Alzheimer's disease, could receive FDA approval by the end of this year. In a Phase 3 study, donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease, with nearly half of the participants showing no clinical progression after one year. The majority of submissions to global regulators are expected to be completed by year's end. Donanemab would be the second Alzheimer's treatment, after Leqembi, to convincingly delay the disease. However, both drugs come with safety concerns, including brain swelling and bleeding.